Following a trial that stopped early: what next for adjuvant hepatic intra-arterial iodine-131 lipiodol in resectable hepatocellular carcinoma?

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Oncology

• Publication date

  2002-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2002.20.6.1709PMID 11896125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monitoring of large randomised clinical trials: a new approach with Bayesian methods.

  2001cited by this paper
• Trials stopped early: too good to be true?

  1999cited by this paper
• Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

  1999cited by this paper
• Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial

  1999cited by this paper
• Bayesian Approaches to Randomized Trials

  1994cited by this paper

• Intra-arterial Therapy of Liver Tumours

  2007cites this paper
• On the evolution of statistical methods as applied to clinical trials

  2004cites this paper
• Strategy for randomised clinical trials in rare cancers

  2003cites this paper
• Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma.

  2003cites this paper